Altretamine 4037380 215528150 2008-05-28T16:29:13Z DOI bot 6652755 Citation maintenance. You can [[WP:DOI|use this bot]] yourself! Please [[User:DOI_bot/bugs|report any bugs]]. {{drugbox | IUPAC_name = N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine | image = Altretamine.svg | CAS_number = 645-05-6 | ATC_prefix = L01 | ATC_suffix = XX03 | ATC_supplemental = | PubChem = 2123 | DrugBank = APRD00652 | C=9 | H=18 | N=6 | molecular_weight = 210.28 g/mol | bioavailability = | protein_bound = 94% | metabolism = | elimination_half-life = 4.7-10.2 hours | pregnancy_category = | legal_status = | routes_of_administration = }} '''Altretamine''' (also '''hexalen''') is a [[drug]] that is used to treat refractory [[ovarian cancer]]. It is not considered a first-line treatment,<ref name="pmid12586589">{{cite journal |author=Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A |title=Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study |journal=Gynecol. Oncol. |volume=88 |issue=2 |pages=118–22 |year=2003 |pmid=12586589 |doi=}}</ref> but it can be useful as salvage therapy.<ref name="pmid14751188">{{cite journal |author=Chan JK, Loizzi V, Manetta A, Berman ML |title=Oral altretamine used as salvage therapy in recurrent ovarian cancer |journal=Gynecol. Oncol. |volume=92 |issue=1 |pages=368–71 |year=2004 |pmid=14751188 |doi=}}</ref> It also has the advantage of being less toxic than other drugs used for treating refractory ovarian cancer.<ref name="pmid11302345">{{cite journal |author=Malik IA |title=Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer |journal=Jpn. J. Clin. Oncol. |volume=31 |issue=2 |pages=69–73 |year=2001 |pmid=11302345 |doi=}}</ref> The precise mechanism by which altretamine exerts its anti-cancer effect is unknown, but it is classified by [[MeSH]] as an [[alkylating antineoplastic agent]]. [[Hydroxymethylmelamines]] are the active metabolite.<ref name="pmid7656502">{{cite journal |author=Damia G, D'Incalci M |title=Clinical pharmacokinetics of altretamine |journal=Clinical pharmacokinetics |volume=28 |issue=6 |pages=439–48 |year=1995 |pmid=7656502 |doi=}}</ref> It was approved by the FDA in 1990. ==Side effects== Side effects include [[nausea]], [[vomiting]], [[diarrhea]] and [[neurotoxicity]]. ==References== <references/> ==External links== *[http://www.meds-help.com/altretamine/ Altretamine] {{Chemotherapeutic agents}} [[Category:Triazines]] {{pharma-stub}}